LMRI

Healthcare

Lumexa Imaging Holdings, Inc. Common Stock

Fundamentals0.0

Price Action0.0

News Sentiment0.0

AI Rating

7.0

Key Drivers

Analyst Upside
Earnings Revisions
Target Caveat

AI
AI Summary

7.0

LMRI now looks less like a simple undervalued grower and more like an execution-and-cash-flow test: profitability, reiterated 2026 guidance, and the HSS JV support the upside case, but the sharp selloff shows investors need proof of margin expansion and free-cash-flow conversion before a rerating is likely.

ExecutionRisk

CashFlow‍

GrowthOpportunity

Price Chart

Loading chart...

Financial Metrics

Revenue (TTM)

Net Income (TTM)

EPS (Q)

MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

0.0

Price Behavior

0.0

Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Sentiment & News

0.0

Key News Insights:

•Analyst Upside
•Earnings Revisions
•Target Caveat

Analyst coverage on LMRI turned notably positive, with consensus price targets implying about 73% upside and improving earnings revisions supporting near-term strength.

AnalystOptimism

UpsidePotential

This news is mildly bullish for LMRI, as stronger analyst sentiment and higher price targets may support short-term buying interest